Imetelstat: a first-in-class telomerase inhibitor
A unique molecule targeting a hallmark of cancer
2018 annual meeting of stockholders
Event details are available
A transformative approach
Disease-modifying potential in hematologic malignancies
Together we can make a difference in patients’ lives
Partnerships are key to our success
A visionary history
Creating a legacy of bold innovation